Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Conditions: Triple Negative Breast Cancer Interventions: Drug: Pembrolizumab; Drug: INBRX-106 Sponsors: Providence Health& Services; Inhibrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials